RESEARCH LETTER
 
TOPICS
REFERENCES (21)
1.
Gregory GA, Robinson TIG, Linklater SE, International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special Interest Group, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 2022; 10: 741-60.
 
2.
Ebrahimpour Y, Khatami S, Saffar M, et al. A comprehensive review of novel advances in type 1 diabetes mellitus. J Diabetes 2025; 17: e70120.
 
3.
Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J 2019; 43: 733-43.
 
4.
Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995; 273: 1605-9.
 
5.
Yuan F, Pfeiffer RM, Julián-Serrano S, et al. Autoimmune conditions and pancreatic cancer risk in older American adults. Int J Cancer 2023; 152: 172-82.
 
6.
Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007; 96: 507-9.
 
7.
Carstensen B, Read SH, Friis S, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 2016; 59: 980-8.
 
8.
Hsu PC, Lin WH, Kuo TH, Lee HM, Kuo C, Li CY. A population-based cohort study of all-cause and site-specific cancer incidence among patients with type 1 diabetes mellitus in Taiwan. J Epidemiol 2015; 25: 567-73.
 
9.
Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? Int J Epidemiol 2015; 44: 379-88.
 
10.
Zhang T, Hua X, Mohindroo C, et al. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. J Natl Cancer Inst 2026; 118: 437-47.
 
11.
Wang C, Liu Z, Zhou Y, et al. Exploring the potential link between autoimmune diseases and pan-cancer: a multidatabase mendelian randomization analysis. J Immunol Res 2025; 2025: 6468979.
 
12.
Getu MA, Zhang X, Ying Y, Gong P. A two-sample Mendelian randomization study of type 1 diabetes and the risk of 22 site-specific cancers. Sci Rep 2025; 15: 11371.
 
13.
Zhao J, Li W, Chen L, Li M, Deng W. Casual effects of type 1 diabetes mellitus on site-specific digestive cancers: a Mendelian randomisation analysis. Front Endocrinol (Lausanne) 2024; 15: 1407329.
 
14.
Lu CN, Liu JB, Chen ZY, et al. The complex interplay between diabetes mellitus and pancreatic carcinogenesis: deciphering multifactorial mechanisms and identifying emerging therapeutic vulnerabilities. Cell Biosci 2025; 15: 135.
 
15.
Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nat Genet 2021; 53: 962-71.
 
16.
Rashkin SR, Graff RE, Kachuri L, et al. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat Commun 2020; 11: 4423.
 
17.
Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 2021; 53: 1415-24.
 
18.
Lin Y, Nakatochi M, Hosono Y, et al. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nat Commun 2020; 11: 3175.
 
19.
Quattrin T, Mastrandrea LD, Walker LSK. Type 1 diabetes. Lancet 2023; 401: 2149-62.
 
20.
Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol 2016; 40: 597-608.
 
21.
Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018; 7: e34408.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top